New drug combo aims to control rare blood cancer
NCT ID NCT02737046
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of belinostat (a cancer drug) and zidovudine (AZT, an HIV drug) as consolidation therapy for adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. Fifteen participants received the drugs to see if it could eliminate cancer cells from the blood and improve disease control. The study also monitored side effects and overall response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belinostat and zidovudine (AZT)
What this could lead to
If it works, this could point toward a more effective consolidation treatment for adult T-cell leukemia-lymphoma, potentially improving long-term control of the disease.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to all patients. The combination may cause serious side effects, and it is not a cure—patients will need ongoing maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami
Miami, Florida, 33136, United States